SCHEMBL3583781

SCHEMBL3583781

COc1ccc(CCOC2CCCCC2N2CCOCC2)cc1OC

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 7/20 0.70
SCN5A Q14524 7/20 0.70
SLC6A4 P31645 1/20 0.70
KCND2 Q9NZV8 5/20 0.69
KCNH2 Q12809 1/20 0.69
ALDH1A1 P00352 4/20 0.53
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
HTT P42858 1/20 0.46
CYP2C19 P33261 1/20 0.46
ALOX15 P16050 2/20 0.44
MAPK1 P28482 2/20 0.44
KDM4E B2RXH2 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
ALOX12 P18054 1/20 0.44
RECQL P46063 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
SIGMAR1 Q99720 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1762424 1.00 KCNA5 (0.70) KCNA5SCN5ASLC6A4KCND2KCNH2
SCHEMBL2624892 1.00 KCNA5 (0.70) KCNA5SCN5ASLC6A4KCND2KCNH2
SCHEMBL1763002 1.00 KCNA5 (0.70) KCNA5SCN5ASLC6A4KCND2KCNH2
SCHEMBL2624919 1.00 KCNA5 (0.70) KCNA5SCN5ASLC6A4KCND2KCNH2
Hydrochloric Acid SCHEMBL907874 0.99 KCNA5 (0.70) KCNA5SCN5ASLC6A4KCND2KCNH2
Hydrochloric Acid SCHEMBL907873 0.99 KCNA5 (0.70) KCNA5SCN5ASLC6A4KCND2KCNH2
Hydrochloric Acid SCHEMBL5635811 0.99 KCNA5 (0.70) KCNA5SCN5ASLC6A4KCND2KCNH2
SCHEMBL2624902 0.94 SLC6A4 (0.62) KCNA5SCN5ASLC6A4KCND2KCNH2
SCHEMBL1762317 0.94 SLC6A4 (0.62) KCNA5SCN5ASLC6A4KCND2KCNH2
SCHEMBL1762363 0.94 SLC6A4 (0.62) KCNA5SCN5ASLC6A4KCND2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029639-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2010-02-04 US claimed
US-7534790-B2 Ion channel modulating compounds and uses thereof CARDIOME PHARMA CORP. (CA) 2009-05-19 US claimed
US-20080070911-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2008-03-20 US claimed
US-20070004718-A1 Ion channel modulating compounds and uses thereof CARDIOME PHAMA CORP. (CA) 2007-01-04 US claimed
US-7101877-B2 Ion channel modulating compounds and uses thereof CARDIOME PHARMA CORP. (CA) 2006-09-05 US claimed
US-20050192208-A2 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2005-09-01 US claimed
US-20050020481-A1 Ion channel modulating compounds and uses thereof BAIN ALLAN I (CA) 2005-01-27 US claimed
EP-1422217-A2 Aminocyclohexyl ether compounds and uses thereof Cardiome Pharma Corp. (CA) 2004-05-26 EP claimed
EP-1087934-B1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF NORTRAN PHARMACEUTICALS INC (CA) 2004-02-25 EP claimed
EP-1087934-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF Nortran Pharmaceuticals Inc. (CA) 2001-04-04 EP claimed
WO-1999050225-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF NORTRAN PHARMACEUTICALS INC. (CA) 1999-10-07 WO claimed
US-20160089361-A1 CONTROLLED RELEASE ORAL FORMULATIONS OF ION CHANNEL MODULATING COMPOUNDS AND RELATED METHODS FOR PREVENTING ARRHYTHMIA CARDIOME PHARMA CORP (CA) 2016-03-31 US disclosed
US-20160008322-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP (CA) 2016-01-14 US disclosed
US-20150099788-A1 CONTROLLED RELEASE ORAL FORMULATIONS OF ION CHANNEL MODULATING COMPOUNDS AND RELATED METHODS FOR PREVENTING ARRHYTHMIA CARDIOME PHARMA CORP (CA) 2015-04-09 US disclosed
EP-2468278-A1 Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia Cardiome Pharma Corp. (CA) 2012-06-27 EP disclosed
US-20050209307-A1 Cardiovascular disorders; antiarrhythmia agents as result od analgesics, anesthetics CARDIOME PHARMA CORP. (CA) 2005-09-22 US disclosed
EP-1422217-A2 Aminocyclohexyl ether compounds and uses thereof Cardiome Pharma Corp. (CA) 2004-05-26 EP disclosed
EP-1087934-B1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF NORTRAN PHARMACEUTICALS INC (CA) 2004-02-25 EP disclosed
EP-1087934-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF Nortran Pharmaceuticals Inc. (CA) 2001-04-04 EP disclosed
WO-1999050225-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF NORTRAN PHARMACEUTICALS INC. (CA) 1999-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099788-A1 CONTROLLED RELEASE ORAL FORMULATIONS OF ION CHANNEL MODULATING COMPOUNDS AND RELATED METHODS FOR PREVENTING ARRHYTHMIA CYP2D6, KCNA6, CYP2A6 KCNA5 31/4885SCN5A 69/4885SLC6A4 250/4885
US-20050020481-A1 Ion channel modulating compounds and uses thereof TRPV1, TRPA1, KCNN2 KCNA5 26/4885SCN5A 54/4885SLC6A4 520/4885
US-20070004718-A1 Ion channel modulating compounds and uses thereof TRPV1, TRPA1, KCNN2 KCNA5 26/4885SCN5A 54/4885SLC6A4 520/4885
US-20050209307-A1 Cardiovascular disorders; antiarrhythmia agents as result od analgesics, anesthetics KCNH1, TRPV1, KCNH2 KCNA5 19/4885SCN5A 20/4885SLC6A4 639/4885
US-20080070911-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF TRPV1, TRPA1, KCNN2 KCNA5 26/4885SCN5A 54/4885SLC6A4 520/4885
US-20160008322-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF TRPV1, TRPA1, KCNN2 KCNA5 26/4885SCN5A 54/4885SLC6A4 520/4885
US-20160089361-A1 CONTROLLED RELEASE ORAL FORMULATIONS OF ION CHANNEL MODULATING COMPOUNDS AND RELATED METHODS FOR PREVENTING ARRHYTHMIA CYP2D6, KCNA6, CYP2A6 KCNA5 31/4885SCN5A 69/4885SLC6A4 250/4885
US-20050192208-A2 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF TRPV1, TRPA1, KCNN2 KCNA5 21/4885SCN5A 46/4885SLC6A4 474/4885
US-20100029639-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF TRPV1, TRPA1, KCNN2 KCNA5 26/4885SCN5A 54/4885SLC6A4 520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.